What is STELFONTA?
STELFONTA is the brand name for tigilanol tiglate injection, approved by the U.S. Food and Drug Administration in November 2020 as the first intratumoral injection for Mast Cell Tumors in dogs. It is recommended for non-metastatic Mast Cell Tumors when the cancer has not spread.
The tumors may be anywhere on the skin surface (cutaneous), and may also be under the skin if located at or below the elbow or hock, so the destroyed tumor can easily slough away.
The active ingredient works by breaking down tumor cell walls, disrupting the tumor’s blood supply, and causing the tumor tissue to detach – leaving a wound that heals without intervention, by second intention.
Who is Bruno?
Bruno is a dog living with existing health conditions who was diagnosed with Mast Cell Tumors. His owner, Berni, wanted to understand what STELFONTA treatment would look like in real life before the injection day. She sought information from world leading veterinary oncologists, spoke with her veterinarian about what to expect, and prepared her home in advance.
Berni’s account below is one owner’s real experience. Every dog is different, and STELFONTA should only be administered by a veterinarian who has assessed the individual case.
Is my dog a candidate?
STELFONTA is only for dogs with non-metastatic Mast Cell Tumors (meaning that your veterinarian has confirmed that the tumor has not spread from where it first started to other parts of your pet’s body). The veterinarian will confirm the tumor type, stage the disease, and check the tumor’s location. Subcutaneous tumors above the elbow or hock – including those on the body, head or neck – must not be injected with STELFONTA because of the risk of dead tumor tissue accumulating in the subcutaneous space and causing severe systemic reactions. Pregnant, nursing or breeding dogs, and dogs on certain concurrent medications, may not be suitable candidates.